Experts Established Screening for Lymphoma During Dupilumab Use
New clinical guidelines aim to help patients identify cutaneous T-cell lymphoma when treated for atopic dermatitis.
Updated on Oct. 12, 2026 in Cancer
Live Poll
Do you trust that current medical guidelines provide sufficient protection against serious prescription drug side effects?
An expert panel recently released guidelines for monitoring patients on dupilumab after research indicated the drug may unmask or exacerbate cutaneous T-cell lymphoma. The protocol now recommends biopsy and T-cell testing for individuals with atypical symptoms or late-onset skin conditions.
Why it matters
Distinguishing between atopic dermatitis and cutaneous T-cell lymphoma is challenging because the two conditions share identical symptoms. Early diagnostic intervention is vital because dupilumab, while effective for eczema, can mask the progression of lymphoma, potentially delaying life-saving care.
A systematic review of 547 patients with a mean age of 58 showed that new or worsening lesions appeared roughly 8.9 months after starting dupilumab. While 70% of follow-up patients achieved remission after stopping the drug, the findings remain based on retrospective analysis of diverse clinical data.
The players
Expert Panel of French and Belgian Dermatologists and Pathologists
A group of 37 specialists from 26 institutions who established consensus guidelines for managing dermatological malignancies.
The details
The panel utilized two rounds of Delphi voting to reach a consensus, with 94% to 100% agreement on screening protocols. The guidelines mandate that patients older than 40 with no history of atopy undergo skin biopsy and T-cell clonality testing before starting treatment. If a test is inconclusive, clinicians should repeat the biopsy within 3 months to monitor for emerging malignancy.
Timeline
January 2, 2025 was the end date for the systematic review literature search.
Repeat biopsy is recommended within 3 months for inconclusive test results.
Health Landscape
This development marks a shift in the standard of care for patients with suspected atopic dermatitis by prioritizing malignancy screening in older adults. It builds on the broader effort to refine the use of biologic therapies in patients with complex, potentially overlapping skin presentations.
If you are over 40 and experiencing new or worsening skin lesions after starting treatment for eczema, it is worth discussing the need for a biopsy with your doctor. These guidelines emphasize that distinguishing between lymphoma and atopic dermatitis is critical for selecting the correct therapeutic path.
The takeaway
The primary insight is that cutaneous T-cell lymphoma can mimic eczema, requiring vigilant screening when using biologics. If you suspect your skin condition is not responding as expected, advocate for a formal skin biopsy and T-cell testing with your dermatologist.
Further reading
Learn more about the latest research and diagnostic standards at our Cancer section.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you trust that current medical guidelines provide sufficient protection against serious prescription drug side effects?
